Natalizumab Treatment in Multiple Sclerosis

KÜRTÜNCÜ M.

NOROPSIKIYATRI ARSIVI-ARCHIVES OF NEUROPSYCHIATRY, cilt.48, ss.56-60, 2011 (SCI-Expanded) identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 48
  • Basım Tarihi: 2011
  • Doi Numarası: 10.4274/npa.y6430
  • Dergi Adı: NOROPSIKIYATRI ARSIVI-ARCHIVES OF NEUROPSYCHIATRY
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, TR DİZİN (ULAKBİM)
  • Sayfa Sayıları: ss.56-60
  • Anahtar Kelimeler: Multiple sclerosis, monoclonal antibody treatment, alpha-4 integrin, natalizumab, PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY, JC VIRUS, DISEASE-ACTIVITY, CONTROLLED TRIAL, INTEGRIN, INTERFERON, ANTIBODIES, THERAPY, ENCEPHALOMYELITIS, EFFICACY
  • İstanbul Üniversitesi Adresli: Hayır

Özet

Natalizumab is the first monoclonal antibody approved for the treatment of multiple sclerosis. It is an alpha 4-integrin antagonist that inhibits transmigration of peripheral lymphocytes through the blood-brain barrier. Natalizumab is recommended only for patients who continue to worsen under interferon or glatiramer acetate treatment or who do not tolerate those treatments. Since this drug might occasionally lead to opportunistic infections such as PML, clinicians should always consider the risk-benefit ratio when they decide to use this treatment. (Archives of Neuropsychiatry 2011:48 Supplement 2:56-60)